Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by khalifathecapon Oct 26, 2020 9:34pm
188 Views
Post# 31786227

That much closer to pre-clinical & clinical programs

That much closer to pre-clinical & clinical programs

News today validates us based on the fact the US Army is serious in furthering our test with Dr. Joseph Golden’s lethal mouse model he’s developed. Today is a huge step forward.

https://globalbiodefense.com/2020/08/27/usamriid-scientists-engineer-first-lethal-mouse-model-for-covid-19/

https://www.army.mil/article/238943/unique_army_lab_answers_nations_call_in_supporting_covid_19_response

Do your DD. There's dollar potential in this stock. Company has a reputation to underpromise and overdeliver. Trading under a $15M market cap may be a thing of the past, and many opportunities don't arise like this very often.

Remember Vaxil has been developing a COVID vaccine since February and were among the first ones to go on the FDA list. They've been at it for months, and their successes in Israel led them to a potential breakthrough opportunity within the USAMRIID. 


<< Previous
Bullboard Posts
Next >>